Delaware

Overview

Delaware legalized medical cannabis via the Delaware Medical Marijuana Act, signed May 13, 2011 and codified at Delaware Code Title 16 Chapter 49A. Adult-use cannabis was legalized in April 2023 when House Bills 1 and 2 became law without Governor John Carney's signature, codified at Delaware Code Title 4 Chapter 13 (the Delaware Marijuana Control Act). The state's licensing build-out has lagged; licensed adult-use retail launched in 2025.

The Office of the Marijuana Commissioner regulates adult-use licensing; the Delaware Division of Public Health administers the medical-marijuana program.

Adult-use (Marijuana Control Act, 2023)

• Public possession: 1 ounce of cannabis flower, 12 grams of concentrate, or 750 mg of THC in infused edibles.
• Home cultivation: prohibited.
• Tax: 15% cannabis excise tax at retail.

Medical program (Medical Marijuana Act, 2011)

Qualifying conditions

Delaware's medical-cannabis program enumerates qualifying conditions including:

• Cancer, glaucoma, HIV/AIDS
• ALS, multiple sclerosis, Parkinson's disease, Alzheimer's disease
• Crohn's disease
• Severe and chronic pain, severe nausea
• Cachexia / wasting
• Seizure disorders, epilepsy
• Post-traumatic stress disorder
• Autism spectrum disorder
• Terminal illness with under-twelve-months prognosis

Patient access

• Possession: up to 3 ounces over any 14-day period under medical registration.
• Home cultivation: prohibited for medical patients (same as adult-use rule).
• Reciprocity: Delaware honors out-of-state medical cards at licensed Delaware medical dispensaries for visiting patients.
• Approved forms: flower, edibles, oils, tinctures, capsules, vapes, topicals.

Recreational penalties

Possession of cannabis in excess of adult-use limits is regulated under Delaware Code Title 16. Over-limit possession is generally a civil violation for small amounts; unlicensed manufacture or distribution scales to misdemeanor or felony.

Patients and caregivers

• Patient minimum age: 18. Minor patients require a parent or legal guardian as designated caregiver plus physician certification.
• Caregiver minimum age: 21.
• Caregivers per patient: up to 1 designated caregiver per patient.
• Caregiver registration: via the Division of Public Health; background check.

Patient registration steps

1. Schedule a visit with a Delaware-licensed physician willing to certify a qualifying condition. Qualifying practitioners include physicians, certified nurse practitioners, and physician assistants registered with the program.
2. The practitioner submits a written certification through the Delaware Division of Public Health Medical Marijuana Program portal.
3. The patient applies through the DPH portal, submits identity documents, proof of Delaware residency, and a current photo. The standard registration fee is $125; reduced to $25 for patients on Medicaid, SSDI, or with proof of military veteran status.
4. Approved patients receive a state-issued ID card valid for one year and renewable. The card authorizes purchases at any licensed Delaware compassion center under medical-program pricing and product-form rules.

Minor patients require a parent or legal guardian as designated caregiver. The caregiver completes a separate application and Delaware State Police background check.

Adult-use retail launch

Adult-use retail sales launched in 2025 after a delayed licensing rollout. The build-out sequence:

• April 2023: Marijuana Control Act became law without Governor Carney's signature (Carney's veto was overridden after a procedural lapse caused the bill to take effect automatically).
• 2023-2024: Office of the Marijuana Commissioner established; rulemaking and licensing processes designed; social-equity license categories defined.
• 2024: initial license applications opened. Conversion pathway for existing medical compassion centers to add adult-use authority adopted.
• 2025: first licensed adult-use retail sales began. Conversion of existing medical compassion centers (Columbia Care, Curaleaf, Compassionate Care Research Institute) provided the initial retail footprint.

The state's small geographic size (three counties, roughly 1 million residents) makes the licensed footprint reasonably accessible statewide, but capacity has been limited during the initial rollout.

Reciprocity and visiting patients

Delaware's framework is dual-track for visitors:

• Adult-use: any visitor 21 or older with a government-issued photo ID may purchase from a licensed adult-use retailer under the 1 oz / 12 g / 750 mg caps.
• Medical: visiting medical-cannabis cardholders may purchase from licensed Delaware medical compassion centers under medical-program pricing and product-form rules. The visitor presents a valid medical card from their home state plus a photo ID.

Reciprocity does not extend any non-purchase protections (employment, federal jurisdiction).

Employment and workplace

The Delaware Medical Marijuana Act includes patient-protection language against employer discrimination on the basis of registry status. The Marijuana Control Act layered additional adult-use considerations but preserved broad employer discretion:

• Safety-sensitive positions: employers may continue to enforce drug-free workplace policies for safety-sensitive roles.
• Federal contractor and DOT-regulated positions: federal drug-free workplace and DOT testing rules supersede state-level protection.
• Pre-employment testing: adult-use cannabis use detected through pre-employment testing remains a permissible basis for adverse hiring action under current Delaware law. Medical patient status provides limited protection.
• Workers' compensation: post-incident testing positive for THC may result in benefit denial unless the patient documents medical use within certified parameters.

Public-employee positions and federal-contractor roles follow federal drug-free workplace rules. Healthcare workers, commercial drivers, law-enforcement officers, and education employees face additional licensing-board exposure beyond employer discipline.

Hemp-derived intoxicants

Delaware has not enacted comprehensive restrictions on hemp-derived intoxicating cannabinoids as of mid-2026. Retail availability of delta-8 THC, delta-10 THC, THC-O, and HHC products has been substantial, particularly through gas-station, vape-shop, and dedicated hemp-retailer channels. The Office of the Marijuana Commissioner has issued guidance noting that hemp-derived intoxicating products are not regulated under the Marijuana Control Act and are not part of the licensed adult-use supply chain.

Recent legislative history

Notable developments since 2023:

• April 2023: HB 1 and HB 2 became law without the Governor's signature, creating the adult-use framework.
• 2023-2024: Office of the Marijuana Commissioner stood up; rulemaking issued; medical-to-adult-use conversion pathway adopted.
• 2025: first licensed adult-use retail sales began.
• 2025-2026: continued legislative work on social-equity licensing, expungement of prior cannabis convictions (HB 132 of 2023 set the framework, with implementation continuing), and on-premises consumption pilots.

The April 2026 federal Schedule III rescheduling order produced no immediate Delaware legislative response.

Federal context

Federal jurisdiction layers additional exposure on federal land, federal courthouses, military installations (Dover Air Force Base), and interstate highways. I-95, I-495, I-295, and US-13 corridors see federal drug-interdiction activity. The Delaware-Pennsylvania, Delaware-Maryland, and Delaware-New Jersey borders all see cross-state purchase patterns: New Jersey adult-use product is freely available across the Delaware River, and Maryland adult-use retail (legal since 2023) is accessible across the southern Delaware border.